Related Experiment Video
Updated: Jan 24, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
Published on: December 19, 2017
COMPARISON OF PEDIATRIC PATIENTS WITH PARS PLANITIS WHO UNDERWENT TREATMENT VERSUS OBSERVATION AT A TERTIARY REFERRAL
Julia L Xia1, Jenny Shunyakova1, Kate M Hwang2
1Department of Ophthalmology, University of Colorado School of Medicine, Aurora, Colorado.
Insights
Not all pediatric pars planitis (PP) patients need treatment. Mild cases can be observed without complications, reducing medication side effects and burden.
Area of Science:
- Ophthalmology
- Pediatric Ophthalmology
Background:
- Pars planitis (PP) is an inflammatory condition affecting the pediatric eye.
- Treatment decisions for pediatric PP are often based on clinical presentation and severity.
Purpose of the Study:
- To compare pediatric patients with pars planitis (PP) who received treatment versus those observed without treatment.
- To identify characteristics of mild pediatric PP cases suitable for observation.
Main Methods:
- Retrospective chart review of pediatric patients diagnosed with pars planitis (PP) between 2000 and 2024.
- Analysis of clinical characteristics, fluorescein angiography (FA) scores, and treatment outcomes.
Main Results:
- Out of 158 eyes, 127 (80.4%) were treated and 31 (19.6%) observed.
- Observed eyes had significantly less inflammation (anterior chamber cell, vitreous cell, haze, optic nerve edema) and lower FA scores.
- The treated group had higher rates of ocular hypertension and glaucoma; no untreated eyes developed complications requiring surgery. Final visual acuity was similar.
Conclusions:
- Pediatric pars planitis (PP) does not always require treatment.
- Mild cases can be safely observed, avoiding treatment-related side effects and medication burden.
- Identifying suitable candidates for observation can optimize patient care and reduce complications.
Purpose:
To compare the characteristics of pediatric patients with pars planitis (PP) who received treatment versus those who were observed without treatment.
Methods:
Retrospective chart review of pediatric patients diagnosed with PP at a tertiary referral center from 2000 to 2024.
Results:
Of 158 eyes from 84 patients with PP, 127 eyes (80.4%) received treatment and 31 eyes (19.6%) were observed. Eyes that were observed presented with less anterior chamber cell ( P < 0.007), vitreous cell ( P = 0.0005), vitreous haze ( P = 0.003), and optic nerve head edema ( P = 0.03). The untreated group had significantly lower total fluorescein angiography scores ( P < 0.0001) than the treated group and specifically scored lower in disc leakage ( P = 0.006) and retinal capillary leakage ( P < 0.0001). In the treated group, 66 eyes (52%) developed ocular hypertension and 24 (18.9%) developed glaucoma, whereas the untreated group had no cases of either. Final visual acuity was similar between treated and untreated groups (20/32 vs. 20/25, P = 0.13), and no untreated eyes developed complications requiring surgery.
Conclusion:
Not all patients with pediatric PP require treatment. Select mild cases may be safely observed without developing sequelae of chronic inflammation. Proper identification of these patients can reduce side effects and medication burden.
Related Concept Videos
Patient-centered Care
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Tertiary Healthcare System

